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Abstract
Osteoporosis is defined as a systemic skeletal disorder that reduces the strength of bone, resulting in an increased risk of fracture. 
Fractures occur, even if an individual is subjected to minimal trauma such as a fall from own body height. The most common 
osteoporotic fractures are fractures of the vertebrae, femur neck and distal forearm but other peripheral fractures also play an 
important role. Osteoporotic fractures are common and will affect at least a third of women over the age of 50 years.1 It not only 
leads to significant morbidity, but also increased mortality. Osteoporosis is an age-related disease. In view of expectations that life 
expectancy is on the rise, the scope of the problem and the burden of the disease will escalate in future. The incidence of osteo-
porotic fractures in South Africa has not been recorded and most of our calculations are derived from Europe and North America. 
A false impression has been created that Black South Africans are not prone to osteoporosis. It is true that ethnic Blacks have a 
lesser tendency to fracture at equivalent bone mineral density (BMD) values than do Europeans. This should however not distract 
from the fact that many Blacks suffer from the avoidable consequences of osteoporotic fractures. The prevention of osteoporotic 
fractures is a national priority for all our people. It is therefore obvious that the modern family physician needs to have a basic 
knowledge of the disease condition and a strategy for the prevention of fractures.
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Pathophysiology
A continuous process of remodelling maintains normal bone health and 
bone strength. Osteoclasts remove old bone (resorption). Osteoblasts 
replace this with new bone (formation). Under circumstances of normal 
bone turnover these two processes are closely linked and do not 
result in any loss or gain of bone. In osteoporosis, bone turnover is 
increased and resorption is favoured, resulting in loss of bone strength. 
Natural aging in men and women leads to a loss of about 0.5% in bone 
mass per year after the age of 35. In women, lack of oestrogen after 
menopause results in acceleration of resorption and associated bone 
loss. Pharmacological compounds used in osteoporosis either inhibit 
absorption or stimulate formation. Various medical conditions such 
as hyperparathyroidism or drugs such as glucocorticoids, alcohol or 
nicotine may influence bone turnover and cause osteoporososis.
Prevention and treatment
In most aspects of life, prevention is better than cure. This is certainly 
also valid in the field of osteoporosis. Until the first fracture occurs, 
osteoporosis is a silent disease, without any symptoms or increased 
morbidity. Once the first fracture has occurred the risk of subsequent 
fractures doubles with every new fracture, with a resultant increase 
in morbidity and mortality.2 The aim of any osteoporosis prevention 
strategy must be the prevention of fracture. The aim should never 
be the treatment (or improvement) of a single risk factor, such as 
bone BMD. As the disease affects such a large proportion of the 
postmenopausal female population a broad-based approach of all 
menopausal women seems attractive. This is only possible when 
using non-pharmacological strategies such as life-style changes and 
exercise. When using pharmacological strategies, cost-effectiveness, 
compliance and possible adverse events dictate that a case-specific 
approach be followed. This means that only the patient at significant 
risk of fracture must be targeted 
Preventative measures for all postmenopausal women
1.  Lifestyle changes
  Management of the first visit after the last menstrual period 
(menopause) should always include reference to lifestyle changes 
that can promote bone health. All possible bone toxic substances 
should be avoided. The most common bone toxic substance is 
nicotine derived from cigarette smoking.3 The excessive intake 
of alcohol is also a source of bone toxicity.4 Medical history 
should search for the presence, and review the use, of any 
chronic medication toxic to bone, such as high dose systemic 
glucocorticoids or anticonvulsants.
  Inactivity favours osteoclastic activity, with a resultant loss of BMD. 
Weight-bearing exercise on the other hand stimulates osteoblastic 
activity, with a resultant gain in BMD. Daily walking as well as 
specific weight bearing exercise have been found to slow down the 
normal bone loss associated with aging and should be encouraged 
in all postmenopausal women.5 Patients in institutions need special 
evaluation by a physiotherapist.
  Postmenopausal women should be encouraged to implement 
changes that can reduce the risk of falling.6 Special attention must 
be given to all household flooring surfaces as well as the choice of 
appropriate footwear. Balance can be improved by the correction of 
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eyesight and treatment of middle ear pathology. Special attention 
should be given to medication that can promote falls such as 
antidepressants and tranquilizers. This can in some instances be 
addressed by reducing the dose to appropriate levels.
2. Diet and supplementation
  Caregivers and patients are well aware of the important role of 
calcium and vitamin D in bone health. The role of a well balanced 
diet is often overlooked. Bone has an extensive protein matrix that 
needs to be maintained. Normal muscle mass around bone acts 
as fracture protection. Normal muscle function is needed to keep 
balance intact and depends on a well balanced diet, which is often 
lacking in the older patient. All postmenopausal women should 
concentrate on a diet rich in fruit and vegetables, with minimum fat 
intake. Protein supplementation should be considered, especially in 
the frail, and after fracture.
  Normal body homeostasis depends on the maintenance of 
appropriate serum calcium levels. Bone acts as a reservoir 
of calcium. In the event of low availability of calcium (such as 
low dietary intake or absorption), it is mobilised from bone by, 
amongst others, the effect of parathyroid hormone (secondary 
hyperparathyroidism). This leads to increased bone fragility. 
Postmenopausal women need a total recommended dietary 
allowance (RDA) of 1200 mg of elemental calcium.7 The best 
dietary source of calcium is dairy products because of the 
favourable elemental calcium content, the ability to be absorbed, 
and cost-effectiveness. Routine dietary supplementation is only 
needed when dietary sources are inadequate, in patients older than 
60 years or in patients on treatment for osteoporosis. Depending 
on the routine dietary content, daily supplementation with 500 mg 
of elemental calcium carbonate or citrate will be sufficient. There is 
no routine blood test that can detect calcium insufficiency, but low 
levels of 24-hour urinary secretion may be indicative of low calcium 
intake. Daily supplementation of less than 1 500 mg of elemental 
calcium will not promote the formation of renal calculi.
  The role of vitamin D in bone homeostasis has recently been 
redefined.8 It has always been known that vitamin D is essential 
for calcium absorption and the RDA for vitamin D was set at 400 
international units (IU). It is possible to directly determine vitamin 
D status by measuring the blood level of 25-hydroxyvitamin D 
and indirectly by observing the inverse relation with parathyroid 
hormone levels. Using these tools, the optimal 25-hydroxyvitamin 
D level has been set at 30 ng/ml or greater. In order to achieve this 
target the RDA has been raised to 800IU. If this is not done, about 
60% of older patients will have inadequate levels of vitamin D. This 
is caused by age-related inability of the skin and kidney to produce 
the active form of vitamin D. Supplementation is the only option as 
it is impossible to correct the deficit by normal dietary measures. 
Vitamin D supplementation has been shown to independently 
lower the risk of falling in elderly patients.9 In conclusion, it is 
recommended that all patients above the age of 60 years receive 
as supplement 500 mg of elemental calcium and 800IU of vitamin 
D daily.  
Identifying the postmenopausal women at risk of fracture
A case-specific approach is based on the accurate identification of 
any validated risk factor for future fracture. An integrated risk analysis 
model has been commissioned by the World Health Organization 
(WHO), based on the placebo groups of recent large randomised 
clinical trials (RCTs), that will express risk as a percentage over 5 or 10 
years.10 The following risk factors are relevant:
1.   The presence of a fracture or the history of fracture after age 
50 years
  Any prevalent vertebral fracture doubles the risk of subsequent 
fracture. The risk of a subsequent fracture is 20% in the first 
year after vertebral fracture and is increased by the presence of 
multiple fractures. Vertebral fractures may be asymptomatic and 
only detectable by lateral X-ray of the lumbar and cervical spine 
or by lateral vertebral assessment by dual X-ray absorpsiometry 
(DXA). The semi-quantitative method of Genant should be used for 
the evaluation of the vertebral body. This requires at least a 20% 
decline in the anterior, mid or posterior height of the body
2. BMD estimation by DXA
  The diagnosis of osteoporosis historically required the presence of 
a fracture. Bone densitometry by DXA, available since 1990, has 
provided us with a non-invasive, reliable and reproducible index 
that is validated as a good risk factor for fracture.11 A loss of BMD of 
one standard deviation doubles the risk of fracture. The diagnosis 
of osteoporosis using DXA requires a DXA BMD value of 2.5 
standard deviations below the peak value for a young Caucasian 
female (T-score –2.5). Although this definition is useful as an 
epidemiological tool, it is not a good clinical intervention threshold 
value, as it is based on a single risk factor for fracture. The need 
for treatment should also consider other risk factors. A routine DXA 
examination is advised for all postmenopausal women considered 
to be at risk of fracture and all women above the age of 65 years.
3. Advanced age
  The risk of fracture increases with age for any given BMD value. A 
BMD T-score of –2.5 at age 75 years implies a greatly increased 
risk of fracture when compared to the same value at age 50 years.
 
4.  Family history of osteoporosis or fractures in first-degree 
relatives
  The peak bone mass of an individual is largely determined 
genetically. The history of a fragility fracture in a first degree relative 
is highly significant of a personal risk of fracture.
5.  Low body mass index (BMI) 
  A low BMI (< 21 kg/m2) is associated with a low BMD, an increased 
risk of fracture, and may be indicative of dietary deficiencies. 
6. Bone toxins 
  These include glucocorticoids, nicotine, alcohol and aromatase 
inhibitors.
7.  Secondary causes of osteoporosis
 The following conditions are associated with osteoporosis:
 a. Osteogenesis mperfecta
 b. Haemochromatosis
 c. Vitamin D deficiency
 d. Cushing’s disease
 e. Premature menopause
 f. Primary hyperparathyroidism
  g. Malabsorption syndromes (Celiac disease, Chrohn’s disease 
and total gastrectomy)
 h. Multiple myeloma
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 i. Lymphoma and leukemia
 j. Anorexia nervosa
 k. Chronic renal disease
No validated model is available that weighs and integrates risk factors 
to provide clear indications for a case specific approach. The best 
practice in menopausal women at present would be to classify patients 
in two groups, namely those with absolute indications and those with 
possible indications for therapy. (See box 1)
Box 1:  Indications for therapy
Absolute indications for prevention/therapy would be any one of the 
following:
1. DEXA BMD of spine: T score of • ≤ –2.5 at 3 vertebrae L1–L4
2. DEXA BMD of hip: T score • ≤ –2.5 at femur neck or total hip
3. The presence of a fragility fracture irrespective of BMD.
Possible indications for therapy:
1.  Low BMD, also called osteopenia (T score < –1 > –2.5) at any of the 
abovementioned sites plus additional risk factor(s). 
The clinical work-up of a patient with osteoporosis
Evaluation entails history taking and physical examination. Biochemical 
assessment to exclude secondary causes of loss of bone strength 
comprises:
a. Raised serum free calcium is an indication of hyperparathyroidism
b.  Raised serum parathyroid hormone (PTH) is indicative of primary 
hyperparathyroidism. 
c.  Low levels of 25-hydroxyvitamin D is indicative of a vitamin D 
deficiency 
d.  A low calcium level in a 24-hour urine sample is indicative of poor 
calcium intake or absorption
e. Nutritional status may be reflected in a full blood count
f.  A raised erythrocyte sedimentation rate may raise suspicion of an 
underlying malignancy
g. Abnormal serum protein electrophoresis may point to myelomatosis
h.  Paget’s disease is suspected if the serum alkaline phosphatase 
level is raised
i.  Lateral X-rays of the thoracic and lumbar spine are used to exclude 
prevalent vertebral fractures
Pharmacological agents available for the prevention of fracture
Box 2 summarises the different treatment modalities according to their 
pharmacological action. The next section will review each of these 
therapies. 
Box 2: Pharmacological classification of preventative therapies
1. Agents that inhibit resorption (anti-osteoclastic activity) 
 a. Oestrogen/Progestin hormone therapy (EPHT)
 b. Selective oestrogen receptor modulators (SERM)
 c. Bisphosphonates
2. Agents that stimulate bone formation
 • Teriparatide (PTH 1-34)
3. Combination of anti-resorption and formation
 • Strontium Ranelate
1. Agents that inhibit resorption (anti-osteoclastic activity)
 a. Oestrogen/Progestin hormone therapy (EPHT)
  The accelerated bone loss associated with the start of menopause 
is directly related to the abrupt loss of oestrogen caused by ovarian 
failure. It is known that this accelerated loss can be prevented by 
the use of EPHT. It is also known that EPHT increases BMD in 
patients with osteoporosis. Results of the Women’s Health Initiative 
Study (WHI) presented the first evidence in a large RCT that EPHT 
or oestrogen alone (EHT) reduces the risk of all osteoporosis 
related fractures, even in patients at low risk of fracture. Based 
on the initial interpretation and publication of the WHI data, the 
impression was created that any of the advantages of EPHT or 
EHT were overshadowed by possible adverse events. A later 
subgroup analysis in 2007 confirmed the presence of a window of 
opportunity if EPHT is initiated soon after the start of menopause.12 
The initiation of treatment before the age of 60 years pose very little 
risk and may even offer cardiovascular protection.13 It is generally 
not recommended to initiate EPHT after the age of 60 years. The 
continuation of EPHT after the age of 60 years should take into 
account the following:
1.  An increased risk of venous thromboembolism (VTE). The excess 
risk is 18 cases per 10 000 women treated annually and the 
risk increases with age. The effect is maximal in the first year of 
treatment. Risk factors include a previous episode of DVT, or a 
family history of DVT. The risk can be diminished by the use of 
transdermal EPHT, as this avoids the first-pass effect on the liver.  
2.  An increased risk of stroke of approximately 8–12 events per 
10000 women annually. This risk is maintained after the first year of 
treatment. Using lower doses can minimise the risk.
3.  The risk of the diagnosis of breast cancer is slightly increased 
after five years of EPHT (not with oestrogen alone). It is unlikely 
that HT causes breast cancer, but HT may modify the behaviour 
of preexisting breast cancer. This effect increases with duration of 
treatment, as the natural occurrence of breast cancer increases.
The choice of EPHT for bone protection should take into account that 
the effect of HT on BMD is rapidly lost after cessation of therapy. EPHT 
is typically used in the younger patient at risk of fracture, who may also 
suffer from vasomotor symptoms, and may be replaced by another 
agent after the age of 60 years. The fact that all menopausal women 
experience accelerated bone loss at the start of menopause as a result 
of oestrogen loss begs the intuitive question of whether all menopausal 
women should not receive oestrogen replacement therapy. It has been 
calculated that such a population base approach is not feasible and 
that a case specific approach is far superior. 
b. Selective oestrogen receptor modulators (SERMs)
  The only SERM registered in South Africa for fracture protection is 
Raloxifene. Various newer SERMs are presently being developed. 
This complex group of synthetic molecules mimics the good effects 
of oestrogen on bone and lipids, without stimulating the oestrogen 
receptors in breast and endometrium. 
  Raloxifene was shown to reduce the risk of vertebral fracture 
by 34–51% in a large RCT, in spite of a very modest increase in 
BMD.14 Subgroup reanalysis confirmed that vertebral fracture risk 
reduction also applies to osteopenic patients. The risk of invasive 
oestrogen receptor positive breast cancer was reduced by 76%.15 
(Raloxifene© is registered for the prevention of breast cancer in 
osteoporotic patients in South Africa.) A recent RCT proved that the 
drug is as effective as tamoxifene in the prevention of breast cancer 
in non-osteoporotic patients.
  The disadvantage of SERM is that the drug does not treat the 
vasomotor symptoms of menopause and may cause hot flushes. 
Present studies have failed to demonstrate a protective effect on 
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non-vertebral fractures (hip fracture in particular). The RUTH trial 
failed to show that Raloxifene offers protection against coronary 
heart disease in patients at high risk.16 In this trial, patients on 
Raloxifene were at higher risk of venous thrombotic events and 
stroke (risk comparable to that posed by oestrogen). Raloxifene is 
typically used in the patient at risk of vertebral fracture and breast 
cancer.
c. Bisphosphonates
  Alendronate and risedronate are registered in South Africa as 
daily and weekly formulations for the prevention of both vertebral 
and non-vertebral fractures in menopausal osteoporosis, as 
well as in glucocorticoid induced osteoporosis, Paget’s disease 
and osteogenesis imperfecta. Zoledronic acid, ibandronate and 
pamidronate are available as intravenous formulations, but are 
not yet registered for fracture prevention. These drugs share a 
common bisphosphonate structure (P-C-P), with different side 
chains distinguishing the different drugs. Alendronate is the most 
commonly used drug in postmenopausal osteoporosis.
  Oral bisphosphonates are poorly absorbed (less than 1%) and 
must be taken fasting with a glass of water. The patient must 
remain upright and fasting for 30 minutes. Failure to do so may 
cause gastrointestinal side effects or inadequate absorption of the 
drug. 
  The bisphosphonates act against bone resorption by inhibiting 
osteoclast function and reducing bone turnover. Unlike oestrogen 
and raloxifene, the suppression of bone turnover may last for long 
periods after cessation of therapy. The level of suppression varies 
between different bisphosphonates. Bisphosphonates bind tightly 
to hydroxyapatite and are retained in bone for long periods of time. 
When bone is resorbed, metabolically active bisphosphonate is 
again released. This poses a potential risk of oversuppression of 
bone turnover with possible increased fracture risk, but 10 years of 
data on alendronate supports at least a maintained effect on BMD 
without any indications of compromised bone quality
  The decision as to when to start bisphosphonate therapy is 
clear. When to stop therapy is however less clear. The Fracture 
Intervention Trial Long-term Extension (FLEX) study provides some 
answers with regards to alendronate. It has been suggested that 
alendronate can be stopped after five years for a drug-free holiday 
in patients that exhibit a good increase in BMD, with a T-score of 
>–3.5 and no additional risk factors for fracture such as a prevalent 
vertebral fracture.17 It has further been suggested that these 
patients be followed-up by serial BMD, to detect possible fast-
losers of BMD.
  Osteonecrosis of the jaw (OJN) is a condition described as an 
area of exposed alveolar bone in the mandible or maxilla. A recent 
analysis of 368 reported cases provides insight into risk factors 
associated with ONJ.18 Ninety-four per cent of cases had been 
treated with intravenous bisphosphonates at much higher doses 
than used for fracture protection, 84% suffered from multiple 
myeloma or metastatic breast cancer, and 60% were preceded by 
tooth extraction or other dental procedures. 
  Another risk factor is poor oral hygiene. Although the risk of ONJ in 
the management of menopausal osteoporosis is very rare 
 (1:100 000) patients should be counselled and dental examination 
is advised prior to commencing bisphosphonate treatment. Generic 
forms of Alendronate are available in South Africa, with the advantage 
of cost savings. The National Osteoporosis Foundation of South Africa 
has expressed concern about the lack of clinical evidence to support 
the use of these generic drugs. The issue is further confounded 
by the fact that Alendronate to date remains on the list of non-
substitutable drugs. The bisphosphonates have a proven track record 
in osteoporosis and are commonly prescribed for the prevention of 
fractures.  
2. Agents that stimulate bone formation
 Teriparatide (PTH 1-34)
  PTH 1-34 is presently the only pure anabolic agent available in 
South Africa. It is administered daily as a subcutaneous injection. 
If given in this intermittent fashion, PTH improves bone strength by 
stimulation of osteoblast activity (in contrast to the opposite effect if 
high doses of PTH prevail continuously as in hyperparathyroidism). 
When compared with the antiresorptives, PTH causes greater 
increases in BMD. It also improves microarchitecture. Vertebral 
fractures are reduced by 65% and non-vertebral fractures by 
40%. Side effects are generally mild and include hypercalcemia 
and raised uric acid levels, as well as leg cramps, nausea 
and headaches. Early concerns regarding the induction of 
osteosarcoma in rats have not been substantiated in humans.
The use of PTH is limited by high costs. NOFSA has provided the 
following guidelines for the use of teriparatide:19
•  Severe established osteoporosis as defined by low BMD and at 
least two prevalent fractures
•  Failed antiresorptive treatment as defined by an incident fragility 
fracture while compliant to antiresorptive treatment for at least 12 
months or unacceptable loss of BMD on two occasions while on 
treatment
•  Duration of therapy is presently limited to 18 months and should be 
followed by maintenance therapy with an antiresorptive drug
The anabolic effect of PTH is blunted by prior treatment with 
bisphosphonates. It is hoped that the cost of PTH will be reduced in 
future, in order to be able to use this excellent drug in a less restrictive 
way.
3. Combination of anti-resorption and formation
 Strontium ranelate
  Strontium ranelate is registered in South Africa for the treatment of 
menopausal osteoporosis. This agent has a unique double action. 
Based on bone marker studies, strontium ranelate decreases 
resorption and increases formation. This action is mediated by the 
RANK ligand system as well as by a calcium sensing receptor. Two 
large randomised controlled trials (SOTI and TROPOS), as well 
as extension studies, have yielded robust data over 5 years.20 The 
eight year results are expected soon. Strontium ranelate treatment 
results in significant increases in BMD and reductions in the risk of 
vertebral fractures (41%) and hip fractures (36%) in patients with 
osteoporosis. Significant fracture reduction was also demonstrated 
in patients with osteopenia, patients with or without prior fracture, 
patients older than 80 years, and in peripheral fractures. Strontium 
ranelate is provided as a 2 g powder that is dissolved in water. 
Adherence to therapy is good without any significant adverse 
side effects. Strontium ranelate can be considered as first line 
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therapy for the prevention of osteoporosis related fractures in all 
postmenopausal patients at risk of fracture.
Monitoring of therapy
Any patient on therapy should be monitored for the occurrence of 
any asymptomatic incident vertebral fracture. This can be done very 
effectively utilising VFA by DXA. Monitoring is mostly done by serial 
BMD, but results should be interpreted with caution. Monitoring 
intervals should not be shorter than one year (except in patients 
on high doses of glucocorticoids). It is better to compare vertebral 
values in cases where changes occur faster than in the hip. In spite 
of very similar fracture reduction abilities, the various agents have 
different effects on BMD. Raloxifene has a very modest effect on 
BMD, whereas strontium ranelate causes a disproportional raise 
in BMD levels as DXA also measures the strontium salt deposited 
in bone. Oestrogen, bisphosphonates and PTH have a more 
predictable effect on BMD. Comparative BMD measurements should 
take into account inter-device variability as well as inter operative 
variability. A BMD report should comment on whether any change 
in BMD satisfies the least value of significant change as calculated 
for the specific device and operator. The routine monitoring of 
treatment by biochemical markers of bone turnover is presently not 
recommended in routine clinical practice.  
Conclusion
All menopausal patients need to be educated about non-
pharmacological ways of improving bone health. It is important to 
identify menopausal patients at high risk of fracture, as a variety of 
drugs is available with proven anti-fracture efficacy.
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